about
Peptide vaccines for hematological malignancies: a missed promise?Identification of a novel p190-derived breakpoint Peptide suitable for Peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients.Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lara Aprile
@ast
Lara Aprile
@en
Lara Aprile
@es
Lara Aprile
@nl
Lara Aprile
@sl
type
label
Lara Aprile
@ast
Lara Aprile
@en
Lara Aprile
@es
Lara Aprile
@nl
Lara Aprile
@sl
prefLabel
Lara Aprile
@ast
Lara Aprile
@en
Lara Aprile
@es
Lara Aprile
@nl
Lara Aprile
@sl
P1053
K-2363-2016
P106
P21
P31
P3829
P496
0000-0001-6849-0411